Virginia Reichert1, Xiangying Xue2, Diane Bartscherer1, Daniel Jacobsen1, Christine Fardellone1, Patricia Folan1, Nina Kohn3, Arunabh Talwar1, Christine N Metz4. 1. Center for Tobacco Control, The North Shore-LIJ Health System, Manhasset, NY. 2. The Feinstein Institute for Medical Research, The North Shore-LIJ Health System, Manhasset, NY. 3. The Biostatistics Unit, The North Shore-LIJ Health System, Manhasset, NY. 4. The Feinstein Institute for Medical Research, The North Shore-LIJ Health System, Manhasset, NY. Electronic address: cmetz@nshs.edu.
Abstract
BACKGROUND: The links among smoking, inflammation, and cardiovascular disease (CVD) are well established. Several studies have demonstrated that quitting smoking reverses the risk of coronary heart disease within 5 to 10 years. However, the immediate effects of quitting smoking on inflammatory biomarkers associated with CVD risk have not been well described. METHODS: In this pilot study, we examined a panel of circulating inflammatory biomarkers associated with CVD in "at-risk" women during the smoking cessation program. Forty-six women enrolled in a smoking cessation program consented to attend four study visits over 6 to 7 weeks. Health/medical information and blood were collected at each visit. Circulating levels of C-reactive protein (CRP), tumor necrosis factor (TNF), interleukin (IL)-6, soluble TNF receptor (sTNFR)-I, sTNFR-II, and soluble vascular cell adhesion molecule (sVCAM)-1 were measured, and changes between baseline levels (visit 1, while smoking) and visits 2 through 4 were determined. RESULTS: Significant reductions in circulating levels of TNF, sTNFR-I, sTNFR-II, and sVCAM-1 were observed among participants over the course of the smoking cessation program. Serum levels of both IL-6 and CRP declined during the smoking cessation program; the changes were not statistically significant, however. CONCLUSIONS: These findings suggest there are rapid consequences of smoking cessation on inflammatory biomarkers in women at risk for CVD. Additional, larger studies including diverse smokers desiring to quit are required to confirm changes in "measurable milestones" that could serve as motivating factors to assist smokers to quit.
BACKGROUND: The links among smoking, inflammation, and cardiovascular disease (CVD) are well established. Several studies have demonstrated that quitting smoking reverses the risk of coronary heart disease within 5 to 10 years. However, the immediate effects of quitting smoking on inflammatory biomarkers associated with CVD risk have not been well described. METHODS: In this pilot study, we examined a panel of circulating inflammatory biomarkers associated with CVD in "at-risk" women during the smoking cessation program. Forty-six women enrolled in a smoking cessation program consented to attend four study visits over 6 to 7 weeks. Health/medical information and blood were collected at each visit. Circulating levels of C-reactive protein (CRP), tumor necrosis factor (TNF), interleukin (IL)-6, soluble TNF receptor (sTNFR)-I, sTNFR-II, and soluble vascular cell adhesion molecule (sVCAM)-1 were measured, and changes between baseline levels (visit 1, while smoking) and visits 2 through 4 were determined. RESULTS: Significant reductions in circulating levels of TNF, sTNFR-I, sTNFR-II, and sVCAM-1 were observed among participants over the course of the smoking cessation program. Serum levels of both IL-6 and CRP declined during the smoking cessation program; the changes were not statistically significant, however. CONCLUSIONS: These findings suggest there are rapid consequences of smoking cessation on inflammatory biomarkers in women at risk for CVD. Additional, larger studies including diverse smokers desiring to quit are required to confirm changes in "measurable milestones" that could serve as motivating factors to assist smokers to quit.
Authors: W C Willett; A Green; M J Stampfer; F E Speizer; G A Colditz; B Rosner; R R Monson; W Stason; C H Hennekens Journal: N Engl J Med Date: 1987-11-19 Impact factor: 91.245
Authors: Matteo Cesari; Brenda W J H Penninx; Anne B Newman; Stephen B Kritchevsky; Barbara J Nicklas; Kim Sutton-Tyrrell; Russell P Tracy; Susan M Rubin; Tamara B Harris; Marco Pahor Journal: Am J Cardiol Date: 2003-09-01 Impact factor: 2.778
Authors: Anita H J Van Den Biggelaar; Anton J M De Craen; Jacobijn Gussekloo; Tom W J Huizinga; Bastiaan T Heijmans; Marijke Frölich; Tom B L Kirkwood; Rudi G J Westendorp Journal: FASEB J Date: 2004-04-14 Impact factor: 5.191
Authors: John W McEvoy; Khurram Nasir; Andrew P DeFilippis; Joao A C Lima; David A Bluemke; W Gregory Hundley; R Graham Barr; Matthew J Budoff; Moyses Szklo; Ana Navas-Acien; Joseph F Polak; Roger S Blumenthal; Wendy S Post; Michael J Blaha Journal: Arterioscler Thromb Vasc Biol Date: 2015-03-05 Impact factor: 8.311
Authors: Michael Sobel; Shinsuke Kikuchi; Lihua Chen; Gale L Tang; Tom N Wight; Richard D Kenagy Journal: J Vasc Surg Date: 2018-06-15 Impact factor: 4.268
Authors: Joseph Firth; Marco Solmi; Robyn E Wootton; Davy Vancampfort; Felipe B Schuch; Erin Hoare; Simon Gilbody; John Torous; Scott B Teasdale; Sarah E Jackson; Lee Smith; Melissa Eaton; Felice N Jacka; Nicola Veronese; Wolfgang Marx; Garcia Ashdown-Franks; Dan Siskind; Jerome Sarris; Simon Rosenbaum; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2020-10 Impact factor: 49.548